Alleyne, Candice et al. published their research in Journal of Medicinal Chemistry in 2020 | CAS: 86069-86-5

(S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid (cas: 86069-86-5) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.HPLC of Formula: 86069-86-5

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design was written by Alleyne, Candice;Amin, Rupesh P.;Bhatt, Bhavana;Bianchi, Elisabetta;Blain, J. Craig;Boyer, Nicolas;Branca, Danila;Embrey, Mark W.;Ha, Sookhee N.;Jette, Kelli;Johns, Douglas G.;Kerekes, Angela D.;Koeplinger, Kenneth A.;LaPlaca, Derek;Li, Nianyu;Murphy, Beth;Orth, Peter;Ricardo, Alonso;Salowe, Scott;Seyb, Kathleen;Shahripour, Aurash;Stringer, Joseph R.;Sun, Yili;Tracy, Rodger;Wu, Chengwei;Xiong, Yusheng;Youm, Hyewon;Zokian, Hratch J.;Tucker, Thomas J.. And the article was included in Journal of Medicinal Chemistry in 2020.HPLC of Formula: 86069-86-5 The following contents are mentioned in the article:

Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clin. validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein-protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the mol. weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease. This study involved multiple reactions and reactants, such as (S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid (cas: 86069-86-5HPLC of Formula: 86069-86-5).

(S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid (cas: 86069-86-5) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.HPLC of Formula: 86069-86-5

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem